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Objective and Impact Statement. There is a need to develop platforms delineating inflammatory biology of the distal human lung.
We describe a platform technology approach to detect in situ enzyme activity and observe drug inhibition in the distal human lung
using a combination of matrix metalloproteinase (MMP) optical reporters, fibered confocal fluorescence microscopy (FCFM), and
a bespoke delivery device. Introduction. The development of new therapeutic agents is hindered by the lack of in vivo in situ
experimental methodologies that can rapidly evaluate the biological activity or drug-target engagement in patients. Methods. We
optimised a novel highly quenched optical molecular reporter of enzyme activity (FIB One) and developed a translational
pathway for in-human assessment. Results. We demonstrate the specificity for matrix metalloproteases (MMPs) 2, 9, and 13 and
probe dequenching within physiological levels of MMPs and feasibility of imaging within whole lung models in preclinical
settings. Subsequently, in a first-in-human exploratory experimental medicine study of patients with fibroproliferative lung
disease, we demonstrate, through FCFM, the MMP activity in the alveolar space measured through FIB One fluorescence
increase (with pharmacological inhibition). Conclusion. This translational in situ approach enables a new methodology to
demonstrate active drug target effects of the distal lung and consequently may inform therapeutic drug development pathways.
1. Introduction
Respiratory diseases are one of the leading causes of mor-
bidity and mortality worldwide [1]. Despite the significant
burden of disease, there is a paucity of new pharmacologi-
cal moieties reaching clinical phases of development and
even fewer reaching clinical approval with spiraling costs
of drug development [2]. Furthermore, the recent
COVID-19 global pandemic has highlighted the need for
rapid approaches to assess drugs that cause respiratory
morbidity and mortality [3].
To date, the evaluation of early-phase clinical trials in
human pulmonary disease has relied upon measurements,
which include pulmonary function measurements, six-
minute walk tests, and imaging such as computerized
tomography (CT) [4]. These investigations can inform on
functional and structural abnormalities but are delayed
surrogates of active disease and offer little insight into
AAAS
BME Frontiers
Volume 2021, Article ID 9834163, 11 pages
https://doi.org/10.34133/2021/9834163
dynamic molecular processes where therapeutics may be
beneficial. Optical imaging modalities provide the potential
for rapid readouts of disease activity at the site of pathogen-
esis, such as the distal lung [5]. Therefore, we developed a
novel optical imaging approach using a combination of an
existing miniaturized fibred confocal fluorescent micros-
copy (FCFM) system, a bronchoscope compatible delivery
device, a new molecular probe, and a drug inhibitor to
demonstrate real-time drug-target engagement in the distal
lung of patients.
The matrix metalloproteinase (MMP) pathway was
selected for detection and inhibition within a small patient
population (eight patients with predicted aberrant lung
fibrogenesis) to demonstrate the clinical tractability of our
approach. MMPs are mediators of injury and repair, per-
forming pivotal roles in the turnover of the extracellular
matrix (ECM), with dysregulation leading to an aberrant
response in inflammation and tissue repair, which ultimately
leads to an impairment of organ function [6–9]. MMP dys-
regulation has been associated with many acute and chronic
inflammatory respiratory diseases such as acute respiratory dis-
tress syndrome (ARDS) [10], idiopathic pulmonary fibrosis
(IPF) [11], chronic obstructive pulmonary disease (COPD)
[12], and lung cancer [13], with upregulation of the gelatinases
(MMP-2 andMMP-9) often found in IPF [9, 14] and associated
with a more aggressive disease phenotype [15]. The collagenase
MMP-13 has also been shown to be abundant in the IPF tissue,
[16] and as such, there has been considerable interest in the
assessment of pulmonary MMP activity as a biomarker of
fibrotic lung disease [17, 18] and in the therapeutic targeting
of MMP activity in acute and chronic lung disease [19, 20]
and the malignant matrix [21, 22].
The aim of this exploratory translational study was to
develop and assess a novel optical reporter that was able to
image MMP activity (measured though fluorescence increase
of FIB One) within the alveolar space and demonstrate drug-
target engagement using a microdosing approach of a code-
livered MMP inhibitor (moieties delivered being less than
100μg of imaging agent or drug). This methodology and
the demonstration of real-time drug-target engagement in
situ allowed the bedside assessment of pharmacological
action in human disease using optical imaging.
2. Results
2.1. A Tribranched Scaffold Is Efficiently Cleaved by MMPs
with Amplification of Fluorescence Signal within Minutes. We
recently described a MMP peptide substrate [23, 24] that was
selectively and specifically cleaved by secreted MMPs 2, 9, and
13 resulting in fluorescent signal amplification and designed
to be resistant to plasmin and other bystander enzymes. How-
ever, although highly selective, this linear optimised probe dem-
onstrated low signal-to-noise following cleavage.
To maximise the fluorescence amplification, we modified
the linear probe by using a multiple Förster resonance energy
transfer (FRET) system with insertion of the substrate pep-
tide sequence into a tribranched scaffold. This tribranched
structure takes advantage of both the self-quenching effect
observed in multifluorophore constructs [25–27] as well as
the quenching effect of three quenchers [28]. The molecular
probe generated (called FIB One (Figure 1)) consisted of a tri-
branched peptide (Pro-Phe-Gly-Nle-Lys-βAla)3, containing
three fluorescein units and three methyl red groups
(Figure 1). FIB One was prepared using Fmoc-based solid-
phase peptide synthesis (Scheme S1 and ESI), and after
purification, was fully characterized by reverse-phase high-
pressure liquid chromatography (RP-HPLC) and matrix-
assisted laser desorption ionising time-of-flight mass spec-
trometry (MALDI-ToF MS) (Figure 1(b) and ESI).
Selective hydrolysis of the peptidic sequence by the
active enzyme results in an increase in fluorescence due
to the release of the fragments containing fluorescein
(Figure 1(c)), with excitation and emission maxima at
490/530 nm, respectively (Figure 1(d)). FIB One demon-
strated rapid and specific fluorescent amplification when
exposed to recombinant enzymes (MMPs 2, 9, and 13),
which was blocked by the pan-MMP inhibitor marimastat
(Figure 1(e) and Figure S1), with MALDI-ToF MS showing
confirmation of selective cleavage (Figure S1). In addition,
comparison of FIB One with its analogous monomeric
linear structure confirmed improved signal amplification
obtained with the multimeric approach (Figure S2).
2.2. FIB One Is Cleaved by MMPs in Ex Vivo Primary Human
Models and in an Ex Vivo LungModel. To determine the clin-
ical tractability of this approach and for the compound to be
cleaved at physiologically relevant/disease levels of MMPs,
we evaluated the propensity for FIB One to be specifically
cleaved by MMPs 2, 9, and 13 in primary human lung tis-
sue and also by stimulated human neutrophils. FIB One
was cleaved in both these scenarios with cleavage inhibi-
tion observed following coincubation with marimastat
(Figures 2(a) and 2(b)). MALDI-ToF MS confirmed that
the cleavage in these models was MMP specific (Figure S3).
The translational utility required evidence that the MMP
activity could be rapidly detected in the distal lung in real time
(within seconds to minutes) using an endoscopic approach.
Therefore, we utilised an ex vivo ovine lung model
(Figure 2(d)). Here, to demonstrate MMP upregulation, seg-
ments instilled with supernatant from spontaneously occurring
ovine pulmonary adenocarcinoma (OPA) enabled evaluation of
FIB One (Figure 2(c)). FCFM-based imaging of segments with
high MMP activity (Figure S3) confirmed a diffuse pattern of
increased fluorescence across the field of view, which was a
characteristic of cleaved FIB One (Figure 2(d)). In contrast,
vehicle control segments and marimastat (pan-MMP
inhibitor)-dosed segments did not show an increase in FIB
One signal (Figure 2(d)). Together, these data supported that
pulmonary delivery of FIB One could detect MMP activity in
situ when coupled with FCFM within a size relevant model
within physiological concentrations.
2.3. GMP-Manufactured FIB One Demonstrated Stability,
Lack of Toxicity, and Favourable Alveolar Imaging in
Fibrotic Lung Disease in Human Patients. The translational
pathway required toxicological and functional evaluation
of FIB One. FIB One was synthesised in accordance with
active pharmaceutical ingredient (API) development to
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good manufacturing practice (GMP) principles as stated in
Eudralex [29]. It was prepared on a 100mg scale and
demonstrated no degradation as an aqueous formulation
over 12 months (Figure S4 and Table S8). FIB One
demonstrated no overt biological toxicity, as evidenced by
absence of erythrocyte hemolysis, and no preclinical in vivo
toxicity, supported by a rodent intratracheal instillation
model of high FIB One concentrations (500μg/mL,
compared to 20μg/mL for intended human pulmonary
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Figure 1: Structure, characterisation, mode of action, and in vitro validation of FIB One. (a) Chemical structure of FIB One. (b) FIB One
characterisation by MALDI-ToF MS analysis: m/z 6465 [M+H]+). (c) The FIB One structure showing how fluorescence switches from ‘off’
to ‘on’ following cleavage by the target MMP’s. (d) Absorbance and emission spectra of FIB One. (e) Fold-change in fluorescent signal of
FIB One (1 μM) following 10min incubation with target (green) and off-target (black) enzymes, compared to enzyme-free control.
Activation of FIB One by target enzymes was prevented by the addition of the MMP inhibitor marimastat (20 μM, white). Data shows
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Figure 2: Validation of FIB One in physiologically relevant biological models. (a) Fold-change in FIB One (1 μM) signal following 10min
incubation with supernatant from stimulated or nonstimulated neutrophils in vitro with and without a pan-MMP inhibitor, marimastat
(M). Recombinant human MMP-9 (30 nM) shown as reference. Bars show mean (+/-SEM), n ≥ 4 for each condition, analysis by one-way
ANOVA ∗∗∗∗P < 0:0001. MALDI-ToF MS demonstrating site-specific probe cleavage in ESI Figure S3a. (b) Quantification from ex vivo
fibre-based imaging of aged human lung tissue (open circles of pulmonary fibrosis patients and black circles of aged nonfibrotic lung
tissue) with an FCFM imaging system (488 nm excitation). The fluorescence from samples with FIB One (1 μM) or FIB One plus
marimastat (100 μM) was imaged (10min) and quantified. Graph shows fold-change compared to baseline autofluorescence of the same
sample. Data show mean (+/-SEM), n = 9, ∗P = 0:0215, student’s paired t-test. (c) Experimental set-up of size-relevant ex vivo ovine
pulmonary adenocarcinoma (OPA) sheep lung model. (d) Representative images of ex vivo ovine lung and OPA segments following
administration of FIB One with and without inhibitor. Scale bar represents 50μm. Graph demonstrates quantification of all experiments
relative to intrinsic autofluorescence. n = 3, bars show mean (+/-SEM), analysis by paired t-test for each normalised pre-post-FIB One
segment, ∗P = 0:0476.
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recruitment, pulmonary toxicity, or systemic toxicity at
either early or late time points (Table S7).
Using a conventional catheter in the working channel of a
bronchoscope, we delivered FIB One endobronchially as a
bolus to the lungs of eight patients with fibroproliferative lung
disease in which we expected high MMP level (endobronchi-
ally visible tumours and diffuse pulmonary fibrosis). Alveolar
FCFM imaging following endobronchial delivery of the probe
resulted in increased fluorescent signal in all patients with
parenchymal fibrosis (Figure 3). For cancer imaging, ex vivo
data suggested that MMP activity utilising FIB One could be
imaged but in vivo imaging of bronchial tumours was compli-
cated by FIB One washing off the bronchial mucosa rapidly
(Figure S5). There were no significant adverse events in the
eight patients (Supplementary tables S1-S6).
2.4. A Triple Lumen Bronchoscopy Catheter (TLBC) Enabled
Direct Imaging of MMP Activity in the Alveolar Space in
Patients which Was Inhibited by Codelivery of a MMP
Inhibitor. Although we detected MMP activity in patients
with active fibrotic lung disease, our approach was hampered
by requiring the delivery of a proximal bolus of FIB One
down a conventional catheter in a step immediately preced-
ing insertion of the imaging fibre. To enable concurrent FIB
One delivery and imaging at the exact same location, we
developed and deployed a triple lumen bronchoscopy cathe-
ter (TLBC) [30] which allows delivery of compounds and
simultaneous FCFM imaging in the field of view.
To assess the distribution of agents delivered to the lung
parenchyma, we undertook preclinical testing of the TLBC
in an ex vivo ventilated human lung model. 500μL aliquots
of iodinated contrast agent were delivered into the alveolar
space and distribution assessed by CT scan, demonstrating
a dispersal volume of 0.5 cm3 (Figure 4(a)). The TLBC
offered the capability to codeliver microdoses of a drug inhib-
itor. Thus, we reformulated an orally bioavailable small
molecule inhibitor of MMPs (AZD1236) which had been
previously evaluated in Phase-II trials into a GMP aqueous
drug product and evaluated its toxicological and biological






































Figure 3: Imaging of parenchymal fibrosis following delivery of FIB One endobronchially. (a) Representative CT images (axial image from a
patient with rheumatoid arthritis associated interstitial lung disease) with baseline and post-FIB One images acquired by confocal
endomicroscopy imaging. (b) Quantification of in vivo human lung fluorescence measured using confocal endomicroscopy before and
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Figure 4: In vivo evidence of MMP activity with pharmacological inhibition in patients with pulmonary fibrosis. (a) CT images of an inflated
ex vivo human right lung with 500μL aliquots of iodinated contrast delivered transbronchially. (b) Representative in vivo images from a
patient with IPF: (i) alveolar space before administering any agents, (ii) after administering PBS, and (iii, iv) after the administration of
FIB One. Dynamic range is identical for all images. Scale bar represents 20μm. (c) Mean fluorescence of field of view over time during
administration of PBS and FIB One. Corresponding time points to the images in (b) are indicated with arrows. (d) Median fluorescence of
each video from 14 pulmonary segments (nsP = 0:36, ∗∗P = 0:002). Error bars represent mean + / − s:d and statistical values from
Wilcoxon matched pairs. (e) Representative images from a different pulmonary segment in the same patient as in (b): (i) alveolar space
before administering any agents, (ii) after administering MMP inhibitor (AZD1236), and (iii, iv) after the administration of FIB One.
Dynamic range is identical for all images. (f) Mean fluorescence of field of view over time during administration of AZD1236 and FIB
One. Corresponding time points to the images in (e) are indicated with arrows. (g) Median fluorescence of each video from 12 pulmonary
segments dosed with AZD1236 (P = 0:51) or AZD1236 plus FIB One (P = 0:05). Error bars represent mean + / − s:d and statistical values
from Wilcoxon matched pairs. RFU: relative fluorescence unit; PBS: phosphate-buffered saline; AZ: AZD1236 MMP inhibitor.
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Using this approach, we obtained real-time imaging
sequences in nine patients with inflammatory fibroprolifera-
tive disease before and after FIB One delivery, with and
without localised predelivery of AZD1236 (Figure 4,
Table S5 and Figure S6), demonstrating in situ in vivo
drug-target engagement within the alveolar space.
3. Discussion
We report the first in-human pulmonary optical molecular
imaging of enzyme activity, through fluorescence increase
of an MMP reporter, and dynamic elucidation of drug-
target engagement in the distal alveolar regions of the human
lung.
The FIB One probe was specific to MMPs 2, 9, and 13
which degrade gelatin, type IV collagen, and elastin within
the ECM, which are known to be abundant in the context
of acute and chronic inflammation [31] where they are
secreted by infiltrating inflammatory cells as well as bron-
chial and alveolar epithelial cells and fibroblasts [32]. To
ensure future validity of our work, there would need to be
inclusion of a noninflammatory control group to determine
the detection of upregulated vs. homeostatic MMP activity.
However, if confirmed, MMPs represent an attractive target
as they serve as a marker in several human inflammatory dis-
eases including IPF, COPD, ARDS, and lung cancer [10–14].
With the advent of increasingly available multiplexing
approaches for microscopic interrogation, our approach of
using fluorescent reporters with FCFM and drug inhibition
does represent a wider applicability and is readily extendable
to multiple target pathways in several organ systems.
Current approaches to identifying enzyme activity in the
lung has been challenging and has typically been performed
ex vivo using zymography on patient tissue or lavage samples
[33]. However, this technique has several limitations, includ-
ing the requirement for an invasive biopsy and tissue
retrieval and the utilisation of lavage fluid, which is prone
to sampling inconsistencies. Furthermore, zymography
assessment may not reflect free enzyme activity in the native
environment, which in the case of MMPs, is dependent on
inhibitory antagonists such as tissue inhibitors of MMPs
(TIMPs).
Molecular imaging of enzyme activity and pharmacolog-
ical perturbation in vivo has focused on either nuclear imag-
ing of radiolabelled probes or optical imaging with
fluorogenic probes. These studies have used animal models
to image MMP activity in vivo in cancer [34–39], stroke
[40], and joint disease [41–43]; however, they have all relied
on systemic intravenous delivery of the probes and whole-
body optical imaging, which is to date, technically not possi-
ble in humans with sufficient resolution or sensitivity. Thus,
we adopted an alternate approach to measure enzyme activ-
ity in the distal lung human lung, made possible by using
FCFM to allow us to access alveolar regions and deliver
microdoses (<100μg) of FIB One directly to the region of
interest without concerns of toxicity. It was of importance
that the area of tissue imaged coincided with the delivery of
the imaging reagent (FIB One). Whilst our initial endobron-
chial delivery yielded encouraging results, we could not elim-
inate the possibility that FCFM fibre placement would miss a
predosed alveolar region. Our preclinical data supports the
use of this approach in lung cancer, although there were tech-
nical difficulties with imaging endobronchial tumours with
rapid dissipation of probe. These may be mitigated in the
future with further adaptation to the technical approach or
modifications to the probe to allow cancer cell labelling [24].
MMP inhibition has been identified as a target for drug
interventions in inflammatory diseases [44, 45]. MMP inhib-
itors used in trials as cancer therapies were disappointing due
to lack of efficacy and significant adverse effects [46]. Studies
have also been limited by a lack of quantifiable biomarkers to
reflect on their in vivo and functional activity [20]. In this
study, we reformulated and toxicologically qualified
AZD1236, an orally available MMP-9/12 inhibitor which
also demonstrated an ability to inhibit MMPs 2 and 13. It
had previously been used in a phase 2A safety and tolerability
study in 74 emphysema patients randomised to placebo or
AZD1236 75mg twice daily for 6 weeks [19]. The study dem-
onstrated no effect on the secondary lung physiology end-
points, and the investigators were unable to show that
AZD1236 actually inhibited its intended targets in situ.
Indeed, a placebo-controlled, AZD1236 biomarker study of
55 COPD patients again failed to demonstrate MMP-9 or
MMP-12 inhibition in induced sputum [20], whereas we
have demonstrated drug-target engagement of AZD1236 in
humans.
The pathway of drug validation utilises cell-based assays
and animal models of disease followed by phased studies in
humans. At each stage of development, costs increase and
there is a high attrition rate often leading to the failure or
deescalation of drug candidates. Although there are many
reasons for this, one major hurdle is demonstrating that
enzymatic activity is present in the patients being studied.
Therefore, there is a rationale for performing translational
proof of concept (experimental medicine) studies directly
and rapidly in humans, using small numbers of patients.
Consequently, here, we have described a tractable strategy
for rapidly assessing distal alveolar biology using a sensitive
and specific optical probe and direct visualisation of MMP
pathway activity/inhibition in situ in real time with FCFM.
In the future, this could be assessed in a broader group of
patients with inflammatory and noninflammatory lung dis-
ease correlated with the MMP activity and may present the
ability to offer a mechanism-based method of stratifying
patients for drug studies and to interrogate biological path-
ways in situ in vivo with molecular microscopy.
4. Materials and Methods
4.1. Ethics Statement. All experiments using human samples
in vitro were performed following approval of the appropri-
ate regional ethics committee (REC) and with informed
consent of the patients. Blood sample collection and use
was approved by Lothian REC No: 08/S1103/38 and
15/HV/013. Tissue samples were obtained following
approval by NHS Lothian REC and facilitated by NHS
Lothian SAHSC Bioresource REC No: 13/ES/0126 and NHS
Lothian REC No: 09/S1101/52. The ex vivo human lungs
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were deemed unsuitable for transplant and authorised for
research as part of the Enlighten study (London-Central
Research Ethics Committee, REC Reference: 16/LO/1883).
The in-human assessments were undertaken with informed
consent of the participants and approved by the South East
Scotland Regional Ethics Committee 02, REC Number:
15/SS/0235. The trial was registered with ClinicalTrials.gov
(Identifier: NCT02604862).
4.2. In Vitro Enzymatic Validation of FIB One. To determine
the enzymatic specificity of FIB One, the probe was incubated
at a concentration of 1μM (unless otherwise stated) with the
recombinant MMPs (Enzo Life Sciences) (active domains of
MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9,
MMP-10, MMP-11, MMP-12, and MMP-13, all at 30 nM),
thrombin (Sigma Aldrich) (5U/mL), factor Xa (Sigma
Aldrich) (500 nM), plasmin (Sigma Aldrich) (30 nM), and
human neutrophil elastase (30 nM). Where appropriate,
enzymes were incubated with specific inhibitors for 30min
at 37°C prior to addition of FIB One. The pan-MMP inhibi-
tor marimastat (Tocris Biosciences) was used at 20μM, and
the MMP inhibitor AZD1236 was used at 0-14μM. Enzyme
free reactions served as a control. Enzymatic reactions were
performed in MMP buffer (10mM CaCl2, 6.1 g Tris-HCl,
8.6 g NaCl per litre, pH7.5) in a final volume of 20μL. Reac-
tions were performed in duplicate in 384-well plates (Life
Technologies) with optically clear plate seals (Thermo Scien-
tific) and repeated thrice (independently). Fluorescence sig-
nal was measured for up to 60min, ex/em 485/528 nm
using microplate reader (BioTek Synergy H1 multimode
reader). Data were normalised to buffer alone and are pre-
sented as fold-change in signal (relative fluorescent units,
RFU) compared to enzyme-free controls. Data were plotted
using Prism 7 (GraphPad Software Inc., La Jolla, CA, USA).
4.3. Neutrophil Extraction and Evaluation of FIB One.
Neutrophils were isolated from the blood of healthy human
volunteers as previously described [47]. The number of
retrieved neutrophils was determined with NucleoCounter
NC-1000 (Chemo Metec). Neutrophils were resuspended at
a concentration of 20 × 106mL-1 in 0.9% NaCl with 0.9mM
CaCl2. Cells were incubated for 30min at 37
°C. Cells to be
stimulated were subsequently activated with 5μM calcium
ionophore A23187 (Tocris Bioscience) for 30min at 37°C.
Neutrophils were harvested by centrifugation at 400 x g for
5min. Supernatants were removed and stored. Plate reader
assays were performed as described above, with the MMP
buffer replaced with neutrophil supernatant. All experiments
were carried out in duplicate using three independent donors
(one donor per independent repeat). Data were normalised
by background subtraction of intrinsic fluorescence.
4.4. Ex Vivo Human Lung Tissue Processing and Evaluation
of FIB One. Human lung tissue samples (lung tumour and
noncancerous adjacent tissue) were obtained following surgi-
cal resection and stored at -80° C until use. Processing for
multiwell plate reader assay or zymography analysis was con-
ducted as follows: 1mm × 4mm sections were homogenised
in 400μL MMP buffer in Precellys 2.8mm ceramic bead
tubes (VWR) using a Pecellys 24 homogeniser. Homogenised
tissue was adjusted to 4mgmL-1 protein (determined by a
Pierce BCA Total Protein Assay Kit (Thermo Fisher Scien-
tific), following the manufacturer’s instructions). Multiwell
plate reader assays were performed as previously described,
replacing the MMP buffer and MMP enzymes for the homo-
genised and protein-adjusted lung tissue.
For zymography, the samples were mixed 1 : 1 with 2x
SDS sample buffer and 20μL was loaded onto precast
Novex® 10% Zymogram (Gelatin) Protein Gels (Thermo
Fisher Scientific). The gels were placed in an electrophoresis
chamber with pre-chilled Novex diluted running buffer and
electrophoresed at 150V for approximately 90min at 4°C.
Gels were removed and incubated with Novex renaturing
buffer for 90min at 4°C. They were washed in distilled water
and incubated with Novex developing buffer for 30min at
room temperature prior to overnight incubation at 37°C.
Control gels had marimastat (50μM) added to the develop-
ing buffer. Gels were then rinsed with distilled water prior
to staining with a colloidal blue staining kit and imaging
using a transilluminator (UVItec BXT-20M, UVItec Ltd,
Cambridge, UK).
For ex vivo imaging, human lung tissue was sliced into
1mm × 4mm sections and placed in the wells of a 96-well
plate with 100μL of MMP buffer and 30nM MMP-13.
Where appropriate, AZD1236 (0-14μM as indicated in the
text) was added to the tissue and incubated at 37°C for
30min prior to the addition FIB One (5μM). The tissue
was imaged over 10min, 12 frames sec-1 using a preclinical
confocal laser scanning endomicroscopy device (Cellvizio®,
Mauna Kea Technologies, excitation 488 nm/detection band-
width 505 to 700nm) with a compatible imaging fibre
(Alveoflex™, Mauna Kea Technologies). At each time point
60 s, images of captured with same laser power. The fluores-
cence for each sample was calculated by determining the
average fluorescence per frame for each time point. All
images were brightness and contrast enhanced with the same
parameters. Five independent patient specimens were col-
lected and analysed. RFUs collected from off-target frames
(showing motion artefact or absence of any fluorescence)
were omitted during analysis.
4.5. Ex Vivo Lung Experimental Procedure. Ovine pulmonary
adenocarcinoma (OPA) tissue was homogenised using a drill
homogeniser, followed by lysis in cell lysis buffer. The super-
natant was collected following centrifugation at 12,000 rpm
for 20min. The samples were adjusted to 1mgmL-1 total
protein (determined by a Pierce BCA Total Protein Assay
Kit (Thermo Fisher Scientific)). Zymography (as described
above) was performed to confirm MMP activity across mul-
tiple OPA samples. RecombinantMMP-9 (2 nM) and recom-
binant pro-MMP-9 (0.5 nM) were included in the assay as
positive controls.
OPA supernatant (1mL) and marimastat (100μM) or
1mL 0.9% NaCl (control) was instilled into anatomically dis-
tinct segments of ex vivo ventilated non-OPA ovine lungs.
Following >30min, the segments were bronchoscopically
identified and microdosed with 5μM FIB One in 1mL.
FCFM imaging was undertaken pre- and postinstillation
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(Cellvizio®, Mauna Kea Technologies). This was performed
by passing a FCFM fibre into the disparate bronchopulmon-
ary segments (up to 5 passes per bronchopulmonary segment
to capture a regional representation of fluorescence), record-
ing images at 12 frames per second and imaging for up to 5
minutes. Videos were analysed as described above. Each
experimental set was normalised to the control segment
(segment with 1mL 0.9% NaCl instilled) which represents
intrinsic autofluorescence.
4.6. Human Ex Vivo Experimental Procedure. The develop-
ment of the TLBC has been described previously [30]. This
device was compatible with a slimmer (diameter 1mm)
imaging fibre approved for clinical investigation (Miniatur-
ized AlveoFlex™ Confocal Miniprobe, Cellvizio®, Mauna
Kea Technologies) and had two hollow lumens to allow FIB
One and/or AZD1236 drug delivery directly to tissue within
the field of view during image acquisition. The TLBC device
was validated preclinically within ventilated ex vivo human
lungs to assess both fluid delivery capability and to determine
which segments of the lung the device was able to reach.
Iodinated contrast (Omnipaque 300, GE healthcare) was
diluted with PBS in a ratio of 1 : 5 and delivered transbronchi-
ally in 500μL doses through the device lumens to the distal
lung, repeated for multiple pulmonary segments. Following
delivery, the lung was inflated, the trachea clamped, and
computerized tomography (Biograph mCT, Siemens) images
were taken to visualise the extent of alveolar contrast spread.
Processing was performed with Horos DICOM viewer
(HOROS).
4.7. Clinical Study Patient Selection. All participants were
scheduled for routine, clinical diagnostic flexible bronchos-
copy in our institution with a known or suspected diagnosis
of fibrosis or lung cancer. All eight patients had computer-
ized tomography performed prior to bronchoscopy and
regions of active disease identified for targeted investigation.
4.8. Bronchoscopy and FCFM Procedure. Bronchoscopy was
undertaken in an outpatient suite using local anaesthetic
and conscious sedation or in theatre under general anaes-
thetic. FCFM was performed using a clinically approved
confocal laser scanning endomicroscopy device (Cellvizio®,
Mauna Kea Technologies) with a compatible imaging fibre
(Alveoflex™ or Miniaturized Alveoflex™, Mauna Kea
Technologies).
In initial exploratory testing, 8 patients with either endo-
bronchial tumour or parenchymal fibrosis underwent FIB
One microdosing (<100μg, <5mL). FIB One was adminis-
tered using a delivery catheter (ERBE APC catheter or TLBC)
passed out of the working channel of the wedged broncho-
scope into the bronchus allowing distal dissipation of the
compound for alveolar imaging or applied directly onto
visible tumour. FCFM imaging was performed pre- and post-
instillation of FIB One, with the fibre tip positioned at the
bronchial mucosa or passed into the alveolar region follow-
ing transbronchial puncture, as appropriate for the clinical
indication. Images were recorded for at least 30 s at 12
frames/second.
4.9. In Vivo Assessment of FIB One and AZD1236 with TLBC.
In subsequent testing the Miniaturized Alveoflex™-TLBC
combination replaced the Alveoflex™ fibre. The entire appa-
ratus was passed transbronchially to allow direct alveolar
imaging before localised delivery of agents. Once transbron-
chial pass was accomplished, baseline lung imaging was
recorded for at least 30 sec. A 500μL microdose of either
AZD1236 (14μg/mL) or sterile PBS (control) was adminis-
tered under direct observation, and further imaging was
obtained for >60 sec. 500μL of FIB One (20μg/mL) (deliv-
ered only after at least 60s to allowMMP inhibition) was then
dosed to the same area with a further 90-120 sec of imaging
captured. If considerable movement due to breathing or
coughing was encountered, imaging was halted and a new
segment identified. Up to 6 segments of interest were investi-
gated per patient determined by patient tolerance.
4.10. Image Analysis. All video sequences were assessed by
two clinicians with clinical experience of pulmonary endomi-
croscopy. Frames with excessive movement or lack of recog-
nizable alveolar structure were removed from analysis.
Videos were assessed to ensure stability throughout the imag-
ing procedure. To ensure the region imaged was the same as
region dosed, imaging from a segment was excluded if there
was obvious alveolar movement witnessed during image cap-
ture. All video files were analysed using the Cellvizio® Viewer
image processing software from Mauna Kea Technologies,
Paris. A region of interest was drawn around the fibre field
of view and processed to determine the mean RFU for each
frame. The videos were categorized as either baseline, post-
PBS, post-AZD1236, post-FIB One, and PBS or post-FIB
One and AZD1236 for each patient. The median RFU was
calculated for each category and used as a comparative value
between groups.
4.11. Statistical Analysis. Statistical analyses were performed
using Prism 7 (GraphPad Software Inc., La Jolla, CA, USA).
Where appropriate, analyses were performed using the stu-
dent’s t-test or one-way ANOVA. Unless otherwise stated
error bars show standard error of the mean (s.e.m).
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